User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

All Publications

Displaying 8 results.
    • Journal article
    Relapse patterns in early-PET negative, limited-stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy-a joint analysis of EORTC/LYSA/FIL H10 and NCRI RAPID trials.
    Fiaccadori, Valeria Neven, Anouk Fortpied, Catherine Aurer, Igor André, Marc[UCL] Federico, Massimo Counsell, Nicholas Phillips, Elizabeth H Clifton-Hadley, Laura Barrington, Sally F Illidge, Timothy Radford, John Raemaekers, John M M (2023) British journal of haematology — Vol. 200, no. 6, p. 731-739 (2023)
    • Journal article
    Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20+ diffuse large B-cell lymphoma: Final analysis of the collaborative trial in relapsed aggressive lymphoma
    Gisselbrecht, Christian Schmitz, Norbert Mounier, Nicolas Gill, Devinder S. Linch, David C. Trneny, Marek Bosly, André[UCL] Milpied, Noel J. Radford, John Ketterer, Nicolas Shpilberg, Ofer Duḧrsen, Ulrich Hagberg, Hans Ma, D.D. Viardot, Andreas Lowenthal, Ray Brière, Josette Salles, Gilles Moskowitz, Craig H. Glass, Bertram (2012) Journal of Clinical Oncology — Vol. 30, no.36, p. 4462-4469 (2012)
    • Journal article
    Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study.
    Van Den Neste, Eric[UCL] Schmitz, Norbert Mounier, Nicolas Gill, Devinder Linch, David Trněný, Marek Milpied, Nicolas Radford, John Ketterer, Nicolas Shpilberg, Ofer Dührsen, Ulrich Ma, David Brière, Josette Thieblemont, Catherine Salles, Gilles Moskowitz, Craig H Glass, Bertram Gisselbrecht, Christian (2016) Bone Marrow Transplantation — Vol. 51, no. 1, p. 51-57 (2015)
    • Journal article
    Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)
    Herrera, Alex F. Ansell, Stephen M. Zinzani, Pier Luigi Radford, John Maddocks, Kami J. Pinto, Antonio Collins, Graham P. Bachanova, Veronika Bartlett, Nancy L. Bence-Bruckler, Isabelle Hamadani, Mehdi Kline, Justin Mayer, Jiri Savage, Kerry J. Advani, Ranjana H. Caimi, Paolo F. Casasnovas, René-Olivier Feldman, Tatyana A. Hess, Brian T. Bastos-Oreiro, Mariana Iyengar, Sunil Szomor, Árpád Townsend, William André, Marc[UCL] Dyczkowski, Jerzy Eisen, Sandy Urban, Andrzej Pantano, Serafino Cruz, Hans G. Wang, Luqiang Negievich, Yanina Wuerthner, Jens Carlo-Stella, Carmelo (2022) Blood — Vol. 140, no. Suppl 1, p. 3673-3677 (2022)
    • Journal article
    A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma
    Coiffier, Bertrand Radford, John Bosly, André[UCL] Martinelli, Giovanni Barca, Gabriela Davies, Andrew Decaudin, Didier Gallop-Evans, Eve Padmanabhan-Iyer, Swaminathan Van Eygen, Koen Van Den Neste, Eric[UCL] Wu, Ka Lung Gupta, Ira V Lin, Thomas S Goldstein, Nancy Jewell, Roxanne C Winter, Paul Lisby, Steen The 415 study investigators (2013) British Journal of Haematology — Vol. 163, no. 3, p. 334-342 (2013)
    • Journal article
    Maximum Tumor Diameter is Associated with Relapse Risk in Limited-Stage Hodgkin Lymphoma: An International Study.
    Phillips, Elizabeth H Counsell, Nicholas Illidge, Tim M André, Marc[UCL] Aurer, Igor Fiaccadori, Valeria Fortpied, Catherine Neven, Anouk Federico, Massimo Barrington, Sally F Raemaekers, John M Radford, John (2025) Blood advances — (2025)
    • Journal article
    A Randomized Study of Interferon α-2b Versus No Treatment as Consolidation After High Dose Therapy and Autologous Stem Cell Transplantation for Patients With Relapsed Lymphoma.
    Bosly, André[UCL] Grigg, Andrew Holte, Harald Gisselbrecht, Christian Radford, John Rossi, Andrea Lopez-Guillermo, Armando Trneny, Marek Sebban, Catherine Hagberg, Hans Leal da Costa, Fernando Colombat, Philippe Bron, Dominique Coiffier, Bertrand (2013) The Oncologist — Vol. 18, no.11, p. 1189 (2013)
    • Journal article
    The iR regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study.
    Ramchandren, Radhakrishnan Johnson, Peter Ghosh, Nilanjan Ruan, Jia Ardeshna, Kirit M Johnson, Roderick Verhoef, Gregor Cunningham, David de Vos, Sven Kassam, Shireen Fayad, Luis Radford, John Bailly, Sarah[UCL] Offner, Fritz Morgan, David Munoz, Javier Ping, Jerry Szafer-Glusman, Edith Eckert, Karl Neuenburg, Jutta K Goy, Andre (2023) EClinicalMedicine — Vol. 56, p. 101779 [1-15] (2023)